Santhera Pharmaceuticals Holding AG (SWX:SANN)

Revenue by Segment

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Development and Commercialization of products for the treatment of Neuromuscular and Pulmonary Diseases	77.19M	39.12M	103.41M	7.47M	-1.60M
Development and Commercialization of products for the treatment of Neuromuscular and Pulmonary Diseases Growth	97.32%	-62.17%	1283.84%	-	-
Total	77.19M	39.12M	103.41M	7.47M	-1.60M
Total Growth	97.32%	-62.17%	1283.84%	-	-

Revenue by Geography

Financials in millions CHF. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Asia	6.52M	12.79M	1.92M	11.19M	-
Asia Growth	-49.02%	565.96%	-82.83%	-	-
North America	46.29M	11.35M	98.09M	-	-
North America Growth	307.67%	-88.43%	-	-	-
Europe	24.38M	14.97M	3.40M	-3.72M	-1.60M
Europe Growth	62.83%	340.04%	-	-	-
Total	77.19M	39.12M	103.41M	7.47M	-1.60M
Total Growth	97.32%	-62.17%	1283.84%	-	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 23, 2026

Data Sources Report a data error